Key result
Treatment with RA-CHOP in newly-diagnosed DLBCL was well tolerated and safe, yielding an overall response rate of 85% and a 12-month progression-free survival of 77%.
Why the study?
Is the combination of bevacizumab, rituximab, and CHOP (RA-CHOP) safe and effective in patients with newly-diagnosed diffuse large B-cell lymphoma?
Population
13 patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL)
Design
Case_series
Follow-up
median 16.9 months
Authors
Loading...
Does not support practice change in DLBCL; leaves open efficacy of bevacizumab addition versus R-CHOP alone.
Is the combination of bevacizumab, rituximab, and CHOP (RA-CHOP) safe and effective in patients with newly-diagnosed diffuse large B-cell lymphoma?
The addition of bevacizumab to R-CHOP (RA-CHOP) is safe and well-tolerated in newly-diagnosed DLBCL, showing promising response rates.
Ganjoo et al. (2006) studied Untreated diffuse large B-cell lymphoma (DLBCL) (n=13). Rituximab, Bevacizumab and CHOP (RA-CHOP) was evaluated on Overall response rate. Treatment with RA-CHOP in newly-diagnosed DLBCL was well tolerated and safe, yielding an overall response rate of 85% and a 12-month progression-free survival of 77%.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: